Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride, when given in high oral doses to pregnant monkeys, caused genital abnormalities in male fetuses, but not in female fetuses or those exposed to intravenous finasteride.

Finasteride effectively treats male pattern hair loss with a 1 mg daily dose.

Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.

Finasteride effectively treats male hair loss, improving growth and density.

LH and hCG reduce certain protein levels in women's skin.

Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.

Three siblings with a rare genetic condition had abnormal sexual development and chose different gender identities, needing surgery and therapy.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

New chemical compounds were made that effectively block an enzyme linked to prostate growth.

Purple corn extract may help reduce prostate enlargement and inflammation.

5α reductase type 2 enzyme mutation and oxidative stress may increase androgenetic alopecia risk in Egyptians.

SRD5A2 gene variations affect PTSD symptoms differently in males and females.

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

Finasteride may cause kidney damage.

Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

Androgen treatment with dihydrotestosterone may help maintain height in patients with 5-α-reductase type 2 deficiency, especially before puberty.

Testosterone and dihydrotestosterone treatments can help with penile growth in males with 5α-reductase type 2 deficiency, with dihydrotestosterone being more effective in infancy.

No consistent link between genotype and phenotype in 5-α-Reductase type 2 deficiency.

Genetic variations may affect how well finasteride works for BPH patients.

Dihydrotestosterone treatment can help penis growth in boys with 5α-reductase deficiency but doesn't fully normalize size after puberty.

Minoxidil may help treat hair loss by reducing the activity of a specific enzyme linked to baldness.

Methylation in specific gene region causes finasteride resistance in some BPH patients.

The study found that two enzymes linked to hair loss are located in different parts of the scalp, supporting a common treatment's effectiveness.

The enzyme type 1 5α-reductase is more active in the hair follicle's lower part than in the skin's outer layer.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.